

Homocysteine, vitamin B12, and folate circulating levels in women with and without polycystic ovary syndrome: A systematic review and meta-analysis

Women's Health
Volume 20: 1–22
© The Author(s) 2024
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/17455057241279039
journals.sagepub.com/home/whe



Juan R Ulloque-Badaracco¹, Ali Al-kassab-Córdova²,
Enrique A Hernández-Bustamante^{3,4},
Esteban A Alarcón-Braga¹ , Juan C Cabrera-Guzmán¹,
Andres A Horruitiner-Mendoza¹, Pamela Robles-Valcárcel¹,
Vicente A Benites-Zapata⁵ and Faustino R Pérez-López⁶

Abstract

Background: Some studies have reported that homocysteine, vitamin B12, and folic acid levels are associated with polycystic ovary syndrome (PCOS), whereas other studies yielded controversial results.

Objectives: This study aimed to systematize the available evidence of homocysteine, vitamin B12, and folate levels in women with and without PCOS.

Design: Systematic review and meta-analysis

Data Sources and Methods: A systematic search without language restrictions was performed on PubMed, Ovid/Medline, Scopus, Embase, and Web of Science. In addition, the reference lists of the selected studies were reviewed. The Newcastle–Ottawa Scale was employed to evaluate the quality of studies. The means and standard deviations of the outcomes were pooled as standardized mean differences (SMDs) with 95% confidence intervals (CI). Furthermore, the DerSimonian and Laird method was employed for the quantitative synthesis.

Results: A total of 75 studies met the eligibility criteria for at least one outcome. Patients with PCOS had higher circulating homocysteine levels than those without (SMD: 0.82; 95% CI: 0.62–1.02, $n = 70$ studies, $p < 0.001$). This trend remained in the sensitivity and subgroup analyses by world regions of studies, assay methods, and insulin resistance. No significant differences were observed in circulating vitamin B12 (SMD: -0.11 ; 95% CI: -0.25 to 0.03 ; $n = 17$ studies, $p = 0.13$) and folate levels (SMD: -0.2 ; 95% CI: -0.68 to 0.27 ; $n = 17$ studies, $p = 0.41$) between patients with and without PCOS.

Conclusions: (i) Patients with PCOS exhibited significantly higher homocysteine levels than those without, and (ii) no significant differences were observed in both vitamin B12 and folate levels in women with and without PCOS.

Registration: PROSPERO ID (CRD42023432883)

¹Facultad de Ciencias de la Salud, Universidad Peruana de Ciencias Aplicadas, Lima, Peru

²Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Universidad San Ignacio de Loyola, Lima, Peru

³Grupo Peruano de Investigación Epidemiológica, Unidad para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru

⁴Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional de Trujillo, Trujillo, Peru

⁵Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru

⁶Instituto Aragonés de Ciencias de la Salud, Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain

Corresponding author:

Vicente A Benites-Zapata, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Email: vbenites@usil.edu.pe



Keywords

Folate, homocysteine, meta-analysis, polycystic ovary syndrome, vitamin B12

Date received: 7 November 2023; revised: 8 August 2024; accepted: 13 August 2024

Introduction

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 116 million women of reproductive age (3.4%) worldwide.^{1,2} The burden of PCOS ascends to 0.43 million disability adjusted life years, and its incidence exhibits an upward trend.³ PCOS entails hirsutism, anovulation, and polycystic ovaries.^{4,5} About 40% of women with PCOS exhibit insulin resistance that can lead to the development of other long-term health conditions, such as diabetes mellitus, infertility, high blood pressure, and coronary diseases.⁶ Although the etiopathogenesis of PCOS remains unclear, various studies in recent years have focused on genetic mechanisms and the role of adipokines.^{7,8}

Part of the main approaches to PCOS treatment has been traditionally addressed on the relief of symptoms, lifestyle changes, dietary modification, increase in physical activity, and other environmental changes (e.g., limit alcohol intake).^{4,9} Obesity is a cofactor in and increases the negative consequences of PCOS, such as glucose intolerance and dyslipidemia, which leads to adverse cardiovascular complications.^{10,11} Dietary modification includes increased consumption of unrefined cereals, beans, fruits, vegetables, lean meat, nuts, seeds and oils, food groups that provide complex carbohydrates, healthy fats, high-quality protein, and micronutrients necessary to improve PCOS condition.^{9,12} Among all nutrients, there is evidence that B complex vitamins, specifically vitamin B12 and folate, exert a beneficial effect on fecundability and fertility. Owing to their role in homocysteine metabolism, intervention studies demonstrated that folate and vitamin B12 supplementation can improve the metabolic profiles of women with PCOS.¹³

Vitamin B12 and folate deficiency can be caused by not only an inadequate diet but also other conditions, such as medications or excessive alcohol intake. Furthermore, gastrointestinal conditions, such as malabsorption, can explain the low serum levels of these vitamins.¹⁴ Insulin resistance is a frequent manifestation in women with PCOS and increases the risk of cardiovascular or metabolic diseases.^{15,16} In this context, these diseases have also been associated with elevated serum homocysteine levels. Likewise, folate and vitamin B12 are necessary for the metabolization of homocysteine; thus, a deficiency of these nutrients could increase the production of homocysteine, thereby exacerbating metabolic and cardiovascular problems.¹⁷ However, there may be other mechanisms that could increase homocysteine levels, such as the presence of chronic inflammation and liver or genetic alterations.^{17–21} Therefore, it is important to synthesize the available evidence regarding the comparison of the serum levels of

homocysteine, folate, and vitamin B12 between healthy women and women with PCOS. This systematic review and meta-analysis aimed to evaluate circulating homocysteine, vitamin B12, and folate levels in women with and without PCOS.

Methods

Registration, report guidelines, and systematic searches

This manuscript was drafted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (see the PRISMA checklist in Supplemental Table S1).²² A summarized version of the protocol was uploaded to the International Prospective Register of Systematic Review and registered under the code CRD42023432883.

The search strategy was established in line with the Peer Review of Electronic Search Strategies Guidelines.²³ The search formula was based on MeSH, Emtree, and free terms. The entire search strategy is provided as a Supplemental Table S2. For this systematic review, hand-searching, citation matching, and date or language restrictions were not applied. PubMed, Web of Science, OVID Medline, Embase, and Scopus were searched. No search was run in preprints repositories, and the reference lists of the included studies were reviewed to seek for additional potential eligible records. The systematic search was simultaneously run in all databases on May 29, 2024.

Eligibility criteria and data extraction

Studies that evaluated the serum levels of homocysteine, vitamin B12, or folate in women with and without PCOS were searched. The inclusion criteria were studies (i) with cross-sectional, case-control, or cohort designs, (ii) that included adolescent and adult women, and (iii) that reported the serum levels of homocysteine, vitamin B12, or folate in women with and without PCOS (control group). PCOS was defined according to the respective meta-analyzed articles and based on international recommendations as specified.

After retrieving records from all the databases, duplicates were removed using EndNote 20.1 and Rayyan QCRI (Rayyan Systems Inc., Doha, Qatar).²⁴ These software were used to screen the titles, abstracts, and full texts of the articles. The screening process was independently performed by two authors (JRUB and AAHM). The full text from the remaining articles were independently reviewed by these authors. Any conflict or discrepancy concerning the inclusion of articles at

any stage of the selection process was resolved by consensus. Afterward, four authors (JRUB, EAAB, EAHB, and JCCG) independently extracted the data from each of the included studies in a preset Google Sheets. In the same manner, any conflict was resolved by consensus. The extracted data included the first author, publication date, study title, study design, study location, PCOS criteria, number of women, age, sex, and serum levels of vitamin B12, folate, and homocysteine in women with PCOS, women PCOS with insulin resistance (PCOS-IR), women with PCOS without insulin resistance (PCOS-NIR), and control group.

Quality assessment and publication bias

Two authors critically and independently evaluated the included studies using the Newcastle–Ottawa Scale²⁵ for the cohort and case–control studies, and an adaptation of the Newcastle–Ottawa Scale for cross-sectional studies. Risk of bias was categorized as having either a low risk of bias (≥ 7 stars) or a high risk of bias (≤ 6 stars). Publication bias was evaluated using the Egger test, considering $p > 0.1$ as indicative of no publication bias.²⁶ Publication bias was also evaluated using funnel plots and, if needed, the trim and fill method.²⁷

Data synthesis and analyses

The effect size of each study was calculated using the mean and standard deviation (SD) of the markers values for women with PCOS versus those without PCOS (control group) and pooled as standardized mean difference (SMD) with 95% confidence interval (CI). RevMan (Cochrane Collaboration®, United Kingdom) was used for the statistical analysis. Values expressed as medians and their interquartile ranges were transformed into means and their corresponding SDs using Hozo et al.'s method.²⁸ Random-effects meta-analyses were conducted using the DerSimonian and Laird method.²⁹ The heterogeneity of the meta-analyses was analyzed using the I^2 statistic ($p \geq 60\%$ was considered to indicate high heterogeneity) and Cochran's Q statistic ($p < 0.1$ was considered as a sign of heterogeneity). Subgroup analyses were conducted by world regions, assay methods, study design, and insulin resistance (PCOS-IR versus PCOS-NIR versus control group). Furthermore, sensitivity analyses were conducted using only studies with low risk of bias.

Results

Study selection and study characteristics

The systematic search led to the identification of 1348 articles, of which 808 remained after the removal of duplicates. In the screening of titles and abstracts, 634 studies were excluded. In turn, full-text screening left 75 studies that met all the eligibility criteria.^{15,30–103} The flowchart of the selection process is shown in Figure 1.




Figure 1. PRISMA flow diagram.

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis.

The systematic review led to the identification of 42 case–control, 25 cross-sectional, and 8 cohort studies. A total of 9962 women were included, of whom 4772 were diagnosed with PCOS. The criteria for diagnosing PCOS were according to the Rotterdam Criteria (72 studies),¹⁰⁴ the United States National Institutes of Health (2 studies),¹⁰⁵ and the Homburg criterion (1 study).¹⁰⁶ The methods employed to measure the serum levels of homocysteine, vitamin B12, and folate were chemiluminescence immunoassay, electrochemiluminescence immunoassay, enzyme-linked immunosorbent assay (ELISA), fluorescence polarization immunoassay, high-performance liquid chromatography, enzyme immunoassay, radioimmunoassay, nephelometry immunoassay, spectrophotometry, and electrophoresis (Table 1).

Quality assessment and publication bias

In the quality assessment, 70 studies were found to have a low risk of bias and 5 had a high risk of bias (Supplemental Table S3). Publication bias was observed when the difference of homocysteine and folate serum levels was evaluated in women with and without PCOS (Egger's test, $p < 0.1$), which were corrected using the trim and fill method for homocysteine (SMD: 0.45; 95% CI: 0.22–0.67; Supplemental Figure S1) and folate (SMD: 0.373; 95% CI: –0.118 to 0.864; Supplemental Figure S2).

Table 1. Characteristics of the included studies in women with and without polycystic ovary syndrome, reporting blood homocysteine, vitamin B12, and/or folate levels.

Author	Year	Country	Median/mean/range age (IQR/SD)	Participants (PCOS/control)	PCOS definition criteria	Marker analyzed	Marker mean (SD) in women with PCOS	Marker mean (SD) in control group	Assay method
Agacayak et al. ³⁰	2015	Turkey	PCOS(+): 26.2 (4) PCOS(-): 27.6 (4.3)	60 (30/30)	Rotterdam	Vitamin B12	256.3 (203.3)	265 (99)	ECLIA
Al-Gareeb et al. ³¹	2016	Iraq	18–42	207 (101/106)	Rotterdam	Homocysteine	11.5 (5.41)	8.10 (1.89)	HPLC
Arkhykina et al. ³²	2016	Ukraine	18–24	90 (70/20)	Rotterdam	Folate	23.54 (0.52)	28.9 (0.7)	Spectrophotometry
Asanidze et al. ³³	2022	Georgia	PCOS(+): 26.8 (3.4) PCOS(-): 25.2 (3.9)	160 (90/70)	Rotterdam	Homocysteine	10.9 (0.3)	8.2 (0.2)	CLIA
Atamer et al. ³⁴	2008	Turkey	PCOS(+): 27.3 (8.3) PCOS(-): 27.9 (8.6)	65 (35/30)	Rotterdam	Homocysteine	12.24 (2.5)	7.2 (2.4)	EIA
Atanasova et al. ³⁵	2017	Macedonia	PCOS(+): 23.9 (3.9) PCOS(-): 24.6 (4.8)	116 (73/43)	Rotterdam	Homocysteine	11.52 (3.11)	6.32 (2.33)	HPLC
Badawy et al. ³⁶	2006	Egypt	PCOS(+): 23.9 (5.62) PCOS(-): 26.7 (4.55)	125 (90/35)	Rotterdam	Homocysteine	11.98 (2.88)	8.5 (3)	EIA
Bahat et al. ³⁷	2021	Turkey	PCOS(+): 24.84 (5.40) PCOS(-): 25.19 (4.53)	200 (100/100)	Rotterdam	Homocysteine	14.32 (5.67)	4.67 (3.11)	CLIA
Battaglia et al. ³⁸	2008	Italy	PCOS(+): 25.2 (4) PCOS(-): 26.5 (4.4)	60 (28/15)	Rotterdam	Homocysteine	11.5 (0.5)	9.8 (1.5)	FPI
Bayrak et al. ³⁹	2012	Turkey	PCOS(+): 21.8 (6.7) PCOS(-): 22.5 (2.6)	102 (77/25)	Rotterdam	Homocysteine	10.7 (1.1)	9.3 (1.8)	FPI
Bayraktar et al. ⁴⁰	2004	Turkey	PCOS(+): 21.4 (3.16) PCOS(-): 21.6 (3.18)	75 (50/25)	National Institutes of Health	Homocysteine	17.7 (3.6)	8.9 (1.9)	HPLC
Bhushan et al. ⁴¹	2022	India	PCOS(+): 23.94 (4.45) PCOS(-): 23.83 (4.64)	70 (35/35)	Rotterdam	Folate	9.3 (3.1)	9.3 (2.7)	CLIA
Cagliar et al. ⁴²	2011	Turkey	PCOS(+): 22.6 (4) PCOS(-): 23.4 (4)	82 (61/21)	Rotterdam	Vitamin B12	251.9 (122.3)	156.2 (129.8)	CLIA
Calzada et al. ⁴³	2018	Spain	PCOS(+): 28 (5) PCOS(-): 30 (6)	294 (125/169)	Rotterdam	Homocysteine	17.93 (9.86)	10.32 (5.95)	CLIA
Cao et al. ⁴⁴	2022	China	PCOS(+): 29.39 (3.16) PCOS(-): 30.6 (2.84)	96 (66/30)	Rotterdam	Homocysteine	10.3 (9.62)	7.5 (3.25)	NR
Celik et al. ⁴⁵	2013	Turkey	PCOS(+): 24.8 (3.80) PCOS(-): 25.02 (3.75)	294 (125/169)	Rotterdam	Homocysteine	10.1 (2.9)	9.3 (2)	Nephelometry
Centinkalp et al. ⁴⁶	2009	Turkey	PCOS(+): 24.58 (4.61) PCOS(-): 25.48 (3.38)	96 (66/30)	Rotterdam	Homocysteine	12.17 (3.64)	10.35 (1.92)	NR
Chakraborty et al. ¹⁵	2013	India	PCOS(+): 28.95 (4.28) PCOS(-): 29.85 (3.69)	86 (44/42)	Rotterdam	Folate	13.74 (8.81)	15.28 (7.51)	NR
Chang et al. ⁴⁷	2019	China	PCOS(+): 27.9 (3.3) PCOS(-): 0	86 (44/42)	Rotterdam	Vitamin B12	384.24 (154.59)	461.34 (193.83)	NR
Cleto et al. ⁴⁸	2010	Brazil	PCOS(+): 26.2 (6.0) PCOS(-): 27.7 (6.1)	220 (129/91)	Rotterdam	Homocysteine	18.49 (6.20)	16.84 (5.06)	EIA
Czerwogrodzka-Senczyna et al. ⁴⁹	2018	Poland	23–46	220 (129/91)	Rotterdam	Homocysteine	2.63 (1.6)	1.33 (0.22)	NR
				243 (126/117)	Rotterdam	Homocysteine	13.14 (0.61)	8.39 (2.22)	CLIA
				1,000 (159/628)	Rotterdam	Homocysteine	7.11 (2.68)	6.73 (2.77)	ELISA
				110 (56/54)	Rotterdam	Homocysteine	5.9 (2)	5.1 (1.3)	ECLIA
				175 (105/70)	Rotterdam	Homocysteine	10.23 (3.21)	9.93 (2.94)	FPI

(Continued)

Table 1. (Continued)

Author	Year	Country	Median/mean/range age (IQR/SD)	Participants (PCOS/control)	PCOS definition criteria	Marker analyzed	Marker mean (SD) in women with PCOS	Marker mean (SD) in control group	Assay method
De la Calle et al. ⁵⁰	2007	Spain	PCOS(+): 28.9 (5.8) PCOS(-): 28.5 (6.6)	78 (39/39)	Rotterdam	Homocysteine Folate	9 (2.1) 7.6 (3.7)	6.4 (1.8) 10.2 (3.6)	HPLC EIA
Deveer et al. ⁵¹	2012	Turkey	PCOS(+): 18.16 (3.07) PCOS(-): 18.20 (2.34)	50 (25/25)	Rotterdam	Vitamin B12 Homocysteine	339 (119) 11.20 (6)	386 (133) 11.50 (5.23)	EIA CLIA
Devi et al. ⁵²	2013	India	PCOS(+): 22.75 (5.60) PCOS(-): 24.25 (5.06)	81 (41/40)	Rotterdam	Homocysteine	18.23 (7.07)	12.1 (3.32)	FPI
Dhamalakshmi et al. ⁵³	2011	India	30–40	100 (50/50)	Rotterdam	Homocysteine	5.42 (0.33)	9.81 (0.24)	NR
Diwakar et al. ⁵⁴	2018	India	> 18	90 (50/40)	Rotterdam	Folate	10.02 (0.68)	7.5 (1.06)	NR
El Gharib et al. ⁵⁵	2016	Egypt	PCOS(+): 28.83 (3.47) PCOS(-): 27.65 (3.67)	100 (60/40)	Rotterdam	Homocysteine	11.8 (5.5)	7.8 (2.29)	FPI
Eskandari et al. ⁵⁶	2016	Iran	PCOS(+): 30.21 (5.41) PCOS(-): 27.67 (5.03)	70 (35/35)	Rotterdam	Homocysteine	26.66 (18.7)	12.97 (5.17)	NR
Esmailzadeh et al. ⁵⁷	2017	Iran	PCOS(+): 23.65 (5.08) PCOS(-): 23.73 (3.85)	80 (60/20)	Rotterdam	Homocysteine Folate	13.27 (7.02) 11.68 (2.92)	9.29 (2.68) 9.31 (2.45)	EIA EIA
Feng et al. ⁵⁸	2021	China	PCOS(+): 27.02 (4.76) PCOS(-): 27.44 (4.21)	450 (150/300)	Rotterdam	Vitamin B12 Homocysteine	392.82 (137.31) 10.07 (2.06)	415.13 (145.38) 8.13 (1.21)	ECLIA EIA
Gözüküçük et al. ⁵⁹	2021	Turkey	PCOS(+): 23.9 (3.6) PCOS(-): 24 (2.9)	86 (45/41)	Rotterdam	Folate Homocysteine	10.49 (3.83) 10.05 (9.77)	11.99 (2.58) 9.87 (9.7)	NR FPI
Gungor et al. ⁶⁰	2021	Turkey	PCOS(+): 24.96 (5.27) PCOS(-): 25.48 (5.36)	200 (109/91)	Rotterdam	Vitamin B12	324 (189.3)	364.71 (127.9)	NR
Gupta et al. ⁶¹	2013	India	PCOS(+): 28.27 (3.36) PCOS(-): 27.4 (2.73)	80 (40/40)	Rotterdam	Homocysteine	6.64 (0.94)	11.04 (4.52)	EIA
Guzelmeric et al. ⁶²	2007	Turkey	PCOS(+): 23.5 (4.7) PCOS(-): 25.9 (5.6)	70 (44/26)	Rotterdam	Homocysteine	13.30 (4.81)	9.02 (3.36)	FPI
Hamadneh et al. ⁶³	2021	Jordan	PCOS(+): 23.58 (0.55) PCOS(-): 34.45 (1.07)	150 (77/73)	Rotterdam	Homocysteine	21.3 (1.88)	16.26 (0.97)	HPLC
Harmanci et al. ⁶⁴	2013	Turkey	PCOS(+): 22.2 (3.5) PCOS(-): 22.2 (3.5)	46 (23/23)	Rotterdam	Homocysteine	13.1 (5.2)	13.4 (4.9)	HPLC
Hemati et al. ⁶⁵	2011	Iran	PCOS(+): 31.09 (8.9) PCOS(-): 29.1 (3.2)	114 (64/50)	Rotterdam	Homocysteine	10.9 (7.2)	6.8 (1.95)	ELISA
Heutling et al. ⁶⁶	2008	Germany	PCOS(+): 27.8 (4.7) PCOS(-): 27.8 (5.6)	122 (83/39)	Rotterdam	Homocysteine	9.3 (3.2)	8.5 (2.1)	HPLC
İsbilen et al. ⁶⁷	2022	Turkey	PCOS(+): 23 (19–27) PCOS(-): 31 (24–39)	140 (101/39)	Rotterdam	Vitamin B12	223.75 (110.3)	219.75 (67.47)	CLIA
Karadeniz et al. ⁶⁸	2010	Turkey	PCOS(+): 24.27 (5.44) PCOS(-): 26.41 (5.65)	156 (86/70)	Rotterdam	Homocysteine	12.315 (3.9)	10.078 (2.247)	FPI
Karaer et al. ⁶⁹	2010	Turkey	PCOS(+): 32.6 (6.6) PCOS(-): 35.6 (5.2)	62 (31/31)	Rotterdam	Homocysteine	10.5 (4.7)	8.03 (1.7)	Competitive immunoassay
Kaya et al. ⁷⁰	2009	Turkey	PCOS(+): 27.2 (4.1) PCOS(-): 26.7 (3.7)	122 (61/61)	Rotterdam	Homocysteine Folate Vitamin B12	13.9 (7.3) 9.2 (2.1) 268.2 (46)	9.4 (2.1) 9.7 (1.3) 308.9 (68.4)	HPLC ECLIA ECLIA

(Continued)

Table 1. (Continued)

Author	Year	Country	Median/mean/range/age (IQR/SD)	Participants (PCOS/control)	PCOS definition criteria	Marker analyzed	Marker mean (SD) in women with PCOS	Marker mean (SD) in control group	Assay method
Kilic-Okman et al. ⁷¹	2004	Turkey	PCOS(+): 23.90 (5.86) PCOS(-): 25.24 (4.28)	54 (29/25)	Rotterdam	Homocysteine	11.11 (5.6)	4.26 (3.1)	CLIA
Krishna et al. ⁷²	2009	India	26–46	112 (56/56)	Rotterdam	Homocysteine	20.21 (1.99)	18.96 (1.93)	ELISA
Kulhan et al. ⁷³	2017	Turkey	PCOS(+): 24.06 (6.12) PCOS(-): 25.34 (5.82)	132 (65/67)	Rotterdam	Folate	19.01 (5.32)	10.79 (5.75)	CLIA
Li et al. ⁷⁴	2022	China	PCOS(+): 26.875 (2.658) PCOS(-): 27.262 (3.030)	871 (208/663)	Rotterdam	Vitamin B12	314.61 (92.95)	300.23 (87.06)	CLIA
Loverro et al. ⁷⁵	2002	Italy	PCOS(+): 23.8 (4.06) PCOS(-): 22.2 (3.1)	55 (35/20)	Rotterdam	Homocysteine	10.4 (4.4)	7.2 (1.5)	HPLC
Maleedhu et al. ⁷⁶	2014	India	20–35	207 (142/65)	Rotterdam	Homocysteine	10.13 (2.8)	7.13 (2.32)	EIA
Miranda-Furtado et al. ⁷⁷	2015	Brazil	PCOS(+): 28.13 (5.45) PCOS(-): 29.62 (5.28)	97 (45/52)	Rotterdam	Homocysteine	7.77 (1.78)	8.27 (6.22)	CLIA
Moran et al. ⁷⁸	2008	Australia	PCOS(+): 32.6 (6.6) PCOS(-): 35.6 (5.2)	30 (14/16)	Rotterdam	Folate	18.5 (6.5)	18.7 (11.3)	NR
Moti et al. ⁷⁹	2015	Iran	PCOS(+): 26.80 (0.67) PCOS(-): 25.10 (0.89)	60 (30/30)	Rotterdam	Vitamin B12	314.5 (142.2)	277.6 (123.9)	NR
Nafiyeh et al. ⁸⁰	2009	Turkey	PCOS(+): 29.61 (5.12) PCOS(-): 29.71 (4.41)	74 (36/38)	Rotterdam	Homocysteine	12.80 (1.7)	9.30 (1.7)	HPLC
Nassir et al. ⁸¹	2020	Sudan	18–46	300 (200/100)	Rotterdam	Homocysteine	7.94 (1.91)	6.77 (2.28)	CLIA
Nazar et al. ⁸²	2017	Iraq	20–35	120 (60/60)	Rotterdam	Homocysteine	14.9 (2.1)	12.1 (2.5)	CLIA
Oktem et al. ⁸³	2009	Turkey	PCOS(+): 25.6 (3.5) PCOS(-): 25.6 (3.8)	62 (31/31)	Rotterdam	Homocysteine	7.39 (2.4)	14.41 (13.73)	ELISA
Onwumere et al. ⁸⁴	2022	Nigeria	PCOS(+): 32 (27.9–35) PCOS(-): 33.5 (3.1–35)	60 (30/30)	Rotterdam	Homocysteine	11.3 (4.8)	9.0 (3.2)	FPI
Orio et al. ⁸⁵	2003	Italy	PCOS(+): 22.5 (4.3) PCOS(-): 21.9 (3.2)	140 (70/70)	Rotterdam	Homocysteine	23.74 (18.13)	10 (1.14)	EIA
Palep-Singh et al. ⁸⁶	2008	England	PCOS(+): 31 (29–33) PCOS(-): 35 (32–37)	41 (25/16)	Rotterdam	Homocysteine	11.3 (3.7)	12.2 (4.5)	HPLC
Peña-Paredes et al. ⁸⁷	2008	Venezuela	PCOS(+): 24 (3.5) PCOS(-): 23.3 (3)	40 (20/20)	Rotterdam	Folate	3.78 (1.05)	3.74 (1.01)	Electrophoresis
Rekha et al. ⁸⁸	2013	India	PCOS(+): 26.10 (4.08) PCOS(-): 27.01 (4.28)	90 (50/40)	Rotterdam	Vitamin B12	377.4 (101.5)	384.5 (128.7)	Electrophoresis
Sadaria et al. ⁸⁹	2021	India	18–35	100 (50/50)	Rotterdam	Homocysteine	9.82 (2.79)	8.03 (2.29)	FPI
Sahin et al. ⁹⁰	2007	Turkey	PCOS(+): 21.6 (3.7) PCOS(-): 22.9 (1.8)	40 (20/20)	Rotterdam	Folate	7.5 (5.7)	10.05 (7.55)	CLIA
Salehpour et al. ⁹¹	2011	Iran	PCOS(+): 29 (5.9) PCOS(-): 27.3 (5.3)	168 (85/83)	Rotterdam	Vitamin B12	394.5 (131.8)	411.5 (112.5)	CLIA
Schachter et al. ⁹²	2015	Israel	28.8 (0.4)	51 (28/23)	Rotterdam	Homocysteine	11.4 (1.8)	6.7 (1.6)	HPLC
Soares et al. ⁹³	2009	Brazil	PCOS(+): 24.5 (3.8) PCOS(-): 24.5 (5.1)	90 (40/50)	Rotterdam	Homocysteine	11.88 (5.55)	7.80 (2.29)	FPI
						Homocysteine	13.9 (3.29)	9.91 (2.88)	EIA
						Homocysteine	12.8 (5.2)	9.9 (2.7)	FPI
						Homocysteine	16.25 (11.94)	11.58 (3.82)	RIA
						Homocysteine	10.5 (0.9)	10.3 (0.9)	FPI
						Homocysteine	6.67 (1.78)	6.47 (1.45)	CLIA

(Continued)

Table 1. (Continued)

Author	Year	Country	Median/mean/range age (IQR/SD)	Participants (PCOS/control)	PCOS definition criteria	Marker analyzed	Marker mean (SD) in women with PCOS	Marker mean (SD) in control group	Assay method
Sohrabvand et al. ⁹⁴	2009	Iran	PCOS(+): 24.27 (3.75) PCOS(-): 25.62 (4.31)	156 (52/104)	Rotterdam	Homocysteine Folate Vitamin B12 Homocysteine	12.21 (4.55) 7.48 (4.37) 323.29 (150.44) 17.00 (4)	13.68 (4.307) 5.43 (3.15) 360.29 (248.99) 9.00 (2.15)	EIA RIA RIA EIA
Suleiman et al. ⁹⁵	2018	Iraq	PCOS(+): 26.88 (6.76) PCOS(-): 27.58 (6.45)	90 (50/50)	Rotterdam	Homocysteine Folate Vitamin B12 Homocysteine	11.5 (2.71) 8.9 (3.45) 352.14 (184.11) 16.25 (6.76)	9.4 (1.8) 9.6 (2.7) 373.2 (117.6) 8.91 (6.47)	CLIA CLIA CLIA EIA
Tarkun et al. ⁹⁶	2005	Turkey	PCOS(+): 24.86 (4.7) PCOS(-): 25.4 (4.07)	75 (40/35)	Rotterdam	Homocysteine Folate Vitamin B12 Homocysteine	11.5 (2.71) 8.9 (3.45) 352.14 (184.11) 16.25 (6.76)	9.4 (1.8) 9.6 (2.7) 373.2 (117.6) 8.91 (6.47)	CLIA CLIA CLIA EIA
Temel et al. ⁹⁷	2010	Turkey	PCOS(+): 23.13 (4.28) PCOS(-): 23.30 (2.76)	60 (30/30)	Rotterdam	Homocysteine Folate Vitamin B12 Homocysteine	11.5 (2.71) 8.9 (3.45) 352.14 (184.11) 16.25 (6.76)	9.4 (1.8) 9.6 (2.7) 373.2 (117.6) 8.91 (6.47)	CLIA CLIA CLIA EIA
Topcu et al. ⁹⁸	2005	Turkey	PCOS(+): 27.1 (4.5) PCOS(-): 28.8 (4.4)	54 (28/26)	Rotterdam	Homocysteine	9.3 (3.1)	6.4 (1.2)	NR
Vrbikova et al. ⁹⁹	2003	Czech Republic	PCOS(+): 25.8 (7) PCOS(-): 33 (5)	51 (40/11)	National Institutes of Health	Homocysteine	10.1 (2.5)	8.78 (2.75)	HPLC
Wijayaratne et al. ¹⁰⁰	2004	Sri Lanka	PCOS(+): 27.3 (1.7) PCOS(-): 33 (4.7)	119 (74/45)	Rotterdam	Homocysteine	10.2 (1.9)	9 (3.8)	FPI
Yarali et al. ¹⁰¹	2001	Turkey	PCOS(+): 27.9 (6.1) PCOS(-): 31.4 (6.5)	60 (30/30)	Rotterdam	Homocysteine Folate Vitamin B12 Homocysteine	11.2 (4.1) 9.3 (4.8) 250.7 (131.9) 14.78 (7.67)	9 (2.4) 9.3 (3) 270.1 (114) 10.45 (5.67)	FPI CLIA CLIA HPLC
Yilmaz et al. ¹⁰²	2005	Turkey	PCOS(+): 23.2 (4.92) PCOS(-): 23.98 (6.08)	135 (85/50)	Homburg	Folate Vitamin B12 Homocysteine	12.96 (3.51) 268.49 (56.78) 13.76 (6.28)	12.78 (3.76) 276.71 (35.89) 9.32 (4.52)	CLIA CLIA HPLC
Yilmaz et al. ¹⁰³	2005	Turkey	PCOS(+): 24.12 (4.89) PCOS(-): 24.35 (5.02)	85 (50/35)	Rotterdam	Folate Vitamin B12 Homocysteine	11.52 (3.14) 312.87 (72.61)	11.83 (3.39) 306.12 (68.35)	HPLC CLIA CLIA

IQR: interquartile range; SD: standard deviation; CLIA: chemiluminescence immunoassay; ECLIA: electrochemiluminescence immunoassay; ELISA: enzyme-linked immunosorbent assay; EIA: enzyme immunoassay; FPI: fluorescence polarization immunoassay; HPLC: high-performance liquid chromatography; NR: not reported; RIA: radio immunoassay; PCOS: polycystic ovary syndrome.

Homocysteine, vitamin B12, and folate meta-analyses

A total of 70 studies ($n=9,400$ participants) evaluated the homocysteine levels in women with and without PCOS. Women with PCOS had higher homocysteine levels than controls (SMD: 0.82; 95% CI: 0.62–1.02; $p < 0.001$; $I^2=94\%$; Figure 2(a)). A total of 17 studies ($n=1,705$ participants) evaluated vitamin B12 levels in women with and

without PCOS. No significant difference was observed in vitamin B12 levels between women with PCOS and the controls (SMD: -0.11 ; 95% CI: -0.25 to 0.03 ; $p=0.13$; $I^2=50\%$; Figure 2(b)). A total of 17 studies ($n=1,945$ participants) evaluated folate levels in women with and without PCOS. No significant difference was observed in the folate levels between women with PCOS and the controls (SMD: -0.2 ; 95% CI: -0.68 to 0.27 ; $p=0.41$; $I^2=96\%$; Figure 2(c)).




Figure 2. (Continued)




Figure 2. Forest plots of studies comparing (a) homocysteine, (b) vitamin B12, and (c) folate in women with and without polycystic ovary syndrome.

Subgroup and sensitivity analyses

In the subgroup analyses by world regions (Figure 3(a)), assay methods (Figure 3(b)), study designs (Figure 3(c)), and insulin resistance (Figure 3(d) and (e)), the differences in homocysteine levels remained with high heterogeneity, except in studies conducted in America continent and in those that evaluated homocysteine levels using the ELISA method. In the sensitivity analysis that included only studies with low risk of bias, women with PCOS were consistently found to have higher homocysteine levels than those without PCOS (SMD: 0.8; 95% CI: 0.59–1.02; $p < 0.01$) without a decrease in heterogeneity ($I^2 = 95\%$; Supplemental Figure S3).

In the vitamin B12 subgroup analyses by world regions (Figure 4(a)), assay methods (Figure 4(b)), study design (Figure 4(c)), and insulin resistance (Figure 4(d) and (e)) did not exhibit significant differences, except in studies conducted in Asia. In the sensitivity analysis that included only studies with low risk of bias, no significant difference was observed between women with and without PCOS (SMD: -0.08 ; 95% CI: -0.25 to 0.08 ; $p = 0.33$; Supplemental Figure S4).

In any of the folate subgroup analyses by world regions (Figure 5(a)), assay methods (Figure 5(b)), study designs (Figure 5(c)), or insulin resistance (Figure 5(d) and (e)) did not significant differences. In the sensitivity analysis, there was no significant difference between women with PCOS and women without PCOS when studies with only low risk of bias were included (SMD: -0.11 ; 95% CI: -0.71 to 0.49 ; $p = 0.71$; Supplemental Figure S5).

Discussion

In this study, patients with PCOS exhibited significantly higher homocysteine levels than those without PCOS.

This association remained significant in (i) the subgroup analyses by world regions and assay methods and (ii) the sensitivity analyses. No significant differences were observed in vitamin B12 and folate levels between women with and without PCOS. Furthermore, there were no differences in the subgroup nor sensitivity analyses for these two outcomes.

Main homocysteine, vitamin B12, and folate metabolism

Homocysteine is a sulfur-containing amino acid does not present in the dietary protein that is an intermediate of methionine metabolism. It plays a role in the remethylation of methionine⁹¹ and transsulfuration of cysteine,¹⁰⁷ requiring vitamins B6 and B12 as well as folate as cofactors for the synthesis.¹⁰⁷ Homocysteine is a biomarker of general health rather than a causal factor, and its serum level is increased in cardiovascular diseases, bone metabolic disorders, renal dysfunction, and neurodegenerative diseases. It is recycled to methionine or converted to cysteine. All tissues can include a methyl group donated by folate. The causes of prime homocysteine imbalance and hyperhomocysteinemia include genetic factors and, less frequently, nutritional and hormonal factors.^{92,108}

Insulin levels may influence homocysteine levels by acting on its glomerular filtration or inhibiting the hepatic cystathionine beta-synthase.^{88,92} Patients with PCOS-IR and those with PCOS-non-IR exhibit increased homocysteine levels, and a correlation exists between homocysteine and insulin levels independent of body mass index (BMI).⁹² In addition, circulating homocysteine is inversely correlated with sex hormone-binding globulin.¹⁰⁹ Follicular homocysteine is a marker of oocyte quality in patients with PCOS, and hyperhomocysteinemia is associated with infertility.¹³ Thus, homocysteinemia has been postulated as a




Figure 3. (Continued)




Figure 3. (Continued)




Figure 3. (Continued)




Figure 3. Subgroup analyses comparing homocysteine in women with and without PCOS: (a) by world regions, (b) by assay methods, (c) by study designs (d) by IR in women with PCOS (PCOS-IR versus PCOS-non IR), and (e) by IR in women with PCOS versus women without PCOS.

PCOS: polycystic ovary syndrome; IR: insulin resistance.

tool for oocyte-embryo selection¹¹⁰ and hyperhomocysteinemia as a risk index of obstetric complications.^{111,112}

Homocysteine, vitamin B12, and folate in patients with PCOS

Hyperhomocysteinemia is a long-term health risk for patients with PCOS, including cardiovascular diseases, chronic kidney disease, hypothyroidism, cognitive decline, and osteoporosis.^{113,114} A previous systematic review and meta-analysis reported significantly higher homocysteine levels in patients with PCOS than in those without,¹¹⁵ with the levels being significantly lower in those with PCOS-non-IR than in those with PCOS-IR.¹¹⁵ Differences in homocysteine levels were also found when the participants were matched for age and BMI.¹¹⁶ Our systematic review and meta-analysis confirmed similar findings based on an updated comprehensive systematic search across multiple databases.

There are specific underlying mechanisms related to the PCOS pathogenesis and its treatment that account for the high homocysteine levels observed in women with the syndrome. Some determinants of elevated homocysteine levels inherent to PCOS have been analyzed, including the correlations between homocysteine and insulin resistance or hyperandrogenism,¹¹⁷ although it remains a debated matter. Methylenetetrahydrofolate reductase (MTHFR) polymorphism was previously considered to be responsible for the high homocysteine levels among women with PCOS.^{85,118} Nevertheless, a recent meta-analysis did not find evidence supporting the association between MTHFR C677T polymorphism and PCOS.¹¹⁹ Meanwhile, despite the decrease in insulin resistance, the use of insulin sensitizers such as metformin or rosiglitazone in patients with PCOS to improve ovulation induction and metabolic parameters has been associated with an elevation in serum homocysteine levels in women with type 2 diabetes mellitus.¹²⁰ Similarly, regardless of smoking and obesity, the plasma homocysteine levels

were increased in patients with PCOS treated with metformin.^{121–124} Interestingly, PCOS patients with obesity have higher homocysteine levels than those who have no obesity.¹²⁵

Folate circulating levels are frequently reduced in patients with PCOS, and folate alone or in combination with B vitamins improve fasting insulin and other outcomes.^{9,13} The administration of B-group vitamins and folic acid reduces circulating homocysteine in patients with PCOS patients, suggesting that such an administration counteracts the homocysteine-increasing effect of metformin therapy.¹²² No significant differences were observed in vitamin B12 and folate between women with and without PCOS.

The pathophysiology of PCOS includes insulin resistance, inflammation, and hormonal imbalances, would drive these links.^{17,70,119} However, PCOS affects heterogeneous populations; therefore, further research is warranted to fully elucidate the specific mechanisms underlying B12 and folate level variations in women with PCOS. To the best of our knowledge, this is the first systematic review that assessed serum vitamin B12 and folate concentrations in women with and without PCOS.

It is premature to suggest treating homocysteine to tackle PCOS with our findings. However, considering the association of hyperhomocysteinemia with the increased risks of cardiovascular, cerebrovascular, and thromboembolic diseases, consider it in treatment.¹¹⁴ Due to the limitations of our study, which are described in the following section, it is impossible to establish temporality or causality. Thus, our findings are merely constrained to associations. Kondapaneni et al.,¹⁶ in their previous nonsystematic literature review, evaluated the importance of homocysteine levels in the overall management of PCOS. They highlighted the need to conduct larger-scale studies with standardized inclusion criteria. In addition, they recommended follow-up on homocysteine levels in women with PCOS at a high risk for complications in their management course.¹⁶




Figure 4. (Continued)




Figure 4. Subgroup analyses comparing vitamin B12 in women with and without PCOS: (a) by world regions, (b) by assay methods, (c) by study designs, (d) by IR in women with PCOS (PCOS-IR versus PCOS-non IR), and (e) by IR in women with PCOS versus those without the syndrome. PCOS: polycystic ovary syndrome; IR: insulin resistance.

Metformin is widely used as an insulin sensitizer in women with PCOS. Nonetheless, a systematic review revealed that it increased the homocysteine levels and decreased the folic acid levels of nonpregnant women with PCOS.¹²⁶ Regarding vitamin B12, another systematic review revealed lower serum levels of this vitamin in patients with PCOS receiving metformin than in the newly diagnosed ones.¹²⁷ Similarly, another systematic review showed that folic acid supplementation improved the BMI of women with PCOS and those with high homocysteine levels.¹²⁸ Accordingly, the supplementation of folic acid and B vitamins would be important for these patients.¹²⁶ A growing evidence has been found regarding the benefits of

such a supplementation on the reproductive health outcomes of women with PCOS.¹³

Limitations and strengths

Our findings should be interpreted considering some limitations. First, there is evidence of substantial statistical heterogeneity attributable to the clinical and methodological variations among the analyzed studies. This would be important for future studies to analyze more clinical and analytical covariates to conduct subanalysis by BMI, physical activity, glycosylated hemoglobin levels, dietary regimen, type of population evaluated, center settings, and




Figure 5. (Continued)




Figure 5. Subgroup analyses comparing folate in women with and without PCOS: (a) by world regions, (b) by assay methods, (c) by study designs (d) by IR in women with PCOS (PCOS-IR versus PCOS non-IR), and (e) by IR in women with PCOS versus women without PCOS.

PCOS: polycystic ovary syndrome; IR: insulin resistance.

others so as to explore the cause of heterogeneity. However, there was no significant reduction in heterogeneity in the sensitivity analysis despite the inclusion of only studies with low risk of bias. Second, most of the effect measures reported in the included studies are subjected to potential confounding. However, in the majority of the reported studies, the effect consistently exhibited the same trend. Third, most of the included studies were from Asia, which raises the need to conduct studies in other populations to evaluate potential variations caused by country-specific factors. Fourth, there is a lack of established threshold values for determining the sensitivity and specificity of homocysteine,

vitamin B12, and folate deficiency in women with PCOS. Therefore, future research should aim to address this gap in different contexts and populations. Fifth, the inclusion of a substantial number of cross-sectional studies in our analysis limits the establishment of causality and restricts our findings to associations rather than causal relationships. Nevertheless, our study also has several strengths. Sensitivity analysis and subgroup analyses were conducted according to diagnostic criteria and world regions. In addition, to the best of our knowledge, this systematic review represents the first attempt to assess the serum levels of vitamin B12 and folate in women with and without PCOS.

Conclusions

Patients with PCOS exhibited significantly higher homocysteine levels than those without PCOS. No significant differences were observed in vitamin B12 and folate levels between women with and without PCOS.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Author contribution(s)

Juan R Ulloque-Badaracco: Conceptualization; Methodology; Formal analysis; Writing – original draft; Investigation; Data curation.

Ali Al-kassab-Córdova: Investigation; Writing – original draft; Data curation; Formal analysis.

Enrique A Hernández-Bustamante: Data curation; Investigation; Writing – original draft.

Esteban A Alarcón-Braga: Investigation; Writing – original draft; Data curation.

Juan C Cabrera-Guzmán: Data curation; Investigation; Writing – original draft.

Andres A Horruitiner-Mendoza: Investigation; Data curation; Writing – original draft.

Pamela Robles-Valcárcel: Investigation; Supervision; Writing – original draft.

Vicente A Benites-Zapata: Investigation; Writing – review & editing; Supervision; Formal analysis; Writing – original draft; Conceptualization; Methodology.

Faustino R Pérez-López: Writing – review & editing; Writing – original draft; Investigation; Formal analysis.

Acknowledgements

None.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

All data generated or analyzed during the current study are included in this published article and its Supplemental Material.

ORCID iDs

Esteban A Alarcón-Braga  <https://orcid.org/0000-0003-3125-5949>

Vicente A Benites-Zapata  <https://orcid.org/0000-0002-9158-1108>

Supplemental material

Supplemental material for this article is available online.

References

1. Jabeen A, Yamini V, Rahman Amberina A, et al. Polycystic ovarian syndrome: prevalence, predisposing factors, and awareness among adolescent and young girls of South India. *Cureus* 2022; 14: e27943.
2. Witchel SF, Burghard AC, Tao RH, et al. The diagnosis and treatment of PCOS in adolescents: an update. *Curr Opin Pediatr* 2019; 31: 562–569.
3. Liu J, Wu Q, Hao Y, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: global Burden of Disease Study 2017. *Hum Reprod* 2021; 36: 1108–1119.
4. Meier RK. Polycystic ovary syndrome. *Nurs Clin North Am* 2018; 53: 407–420.
5. Louwers YV and Laven JSE. Characteristics of polycystic ovary syndrome throughout life. *Ther Adv Reprod Health* 2020; 14: 2633494120911038.
6. Centers for Disease Control and Prevention and PCOS (Polycystic Ovary Syndrome) and Diabetes, <https://www.cdc.gov/diabetes/basics/pcos.html#:~:text=Heart%20disease%E2%80%9494women%20with%20PCOS,the%20risk%20for%20heart%20disease> (2022, accessed 22 October 2023).
7. Guney G, Taşkın MI, Sener N, et al. The role of ERK-1 and ERK-2 gene polymorphisms in PCOS pathogenesis. *Reprod Biol Endocrinol* 2022; 20: 95.
8. Camili FE, Akis M, Adali E, et al. Oncostatin M is related to polycystic ovary syndrome-case control study. *Biomedicine* 2024; 12: 20240202.
9. Cowan S, Lim S, Alycia C, et al. Lifestyle management in polycystic ovary syndrome—beyond diet and physical activity. *BMC Endocr Disord* 2023; 23: 14.
10. Tokmak A, Guzel AI, Güney G, et al. Effect of obesity on clinical parameters and pregnancy rates in women with polycystic ovary syndrome undergoing ovulation induction cycles. *J Reprod Med* 2017; 62: 300–304.
11. Ulloque-Badaracco JR, Al-kassab-Córdova A, Hernandez-Bustamante EA, et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis. *Lipids Health Dis* 2023; 22: 98.
12. Szczuko M, Kikut J, Szczuko U, et al. Nutrition strategy and life style in polycystic ovary syndrome-narrative review. *Nutrients* 2021; 13: 20210718.
13. Thornburgh S and Gaskins AJ. B vitamins, polycystic ovary syndrome, and fertility. *Curr Opin Endocrinol Diabetes Obes* 2022; 29: 554–559.
14. Barnabé A, Aléssio ACM, Bittar LF, et al. Folate, vitamin B12 and homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center. *Nutr J* 2015; 14: 19.
15. Chakraborty P, Goswami SK, Rajani S, et al. Recurrent pregnancy loss in polycystic ovary syndrome: role of hyperhomocysteinemia and insulin resistance. *PLoS One* 2013; 8: e64446.
16. Kondapaneni V, Gutlapalli SD, Poudel S, et al. Significance of homocysteine levels in the management of polycystic ovarian syndrome: a literature review. *Cureus* 2020; 12: e11110.

17. Ulloque-Badaracco JR, Hernandez-Bustamante EA, Alarcon-Braga EA, et al. Vitamin B12, folate, and homocysteine in metabolic syndrome: a systematic review and meta-analysis. *Front Endocrinol* 2023; 14: 1221259.
18. Lazzarini PE, Capocchi PL, Selvi E, et al. Hyperhomocysteinemia, inflammation and autoimmunity. *Autoimmun Rev* 2007; 6: 503–509.
19. Brustolin S, Giugliani R and Félix TM. Genetics of homocysteine metabolism and associated disorders. *Braz J Med Biol Res* 2010; 43: 1–7.
20. Dai H, Wang W, Tang X, et al. Association between homocysteine and non-alcoholic fatty liver disease in Chinese adults: a cross-sectional study. *Nutr J* 2016; 15: 102.
21. Ulloque-Badaracco JR, Al-Kassab-Córdova A, Alarcon-Braga EA, et al. Association of vitamin B12, folate, and homocysteine with COVID-19 severity and mortality: a systematic review and meta-analysis. *SAGE Open Med* 2024; 12: 20503121241253957.
22. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; 339: b2700.
23. McGowan J, Sampson M, Salzweidel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. *J Clin Epidemiol* 2016; 75: 40–46.
24. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. *Syst Rev* 2016; 5: 210.
25. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
26. Egger M, Davey Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; 315: 629–634.
27. Duval S and Tweedie R. A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. *J Am Stat Assoc* 2000; 95: 89–98.
28. Hozo SP, Djulbegovic B and Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005; 5: 13.
29. DerSimonian R and Laird N. Meta-analysis in clinical trials revisited. *Contemp Clin Trials* 2015; 45: 139–145.
30. Agacayak E, Tunc SY, Sak S, et al. Levels of neopterin and other inflammatory markers in obese and non-obese patients with polycystic ovary syndrome. *Med Sci Monit* 2015; 21: 2446–2455.
31. I Al-Gareeb A, Abd Al-Amieer WS, M Alkuraishy H, et al. Effect of body weight on serum homocysteine level in patients with polycystic ovarian syndrome: a case control study. *Int J Reprod Biomed* 2016; 14: 81–88.
32. Arkhpykina TL, Karachentsev YI, Bondarenko VO, et al. The levels of folic acid and homocysteine in the blood of women with polycystic ovary syndrome and the dynamics of these indicators during of folate therapy. *Probl Endocr Pathol* 2016; 56: 7–16.
33. Asanidze E, Kristesashvili J, Parunashvili N, et al. Hyperhomocysteinemia and pregnancy outcomes in women with polycystic ovary syndrome: a case-control study. *Int J Reprod Biomed* 2023; 21: 167–174.
34. Atamer A, Demir B, Bayhan G, et al. Serum levels of leptin and homocysteine in women with polycystic ovary syndrome and its relationship to endocrine, clinical and metabolic parameters. *J Int Med Res* 2008; 36: 96–105.
35. Boshku A, Panova D and Ivanovska B. Association of vascular and inflammatory markers with metabolic disorders in women with polycystic ovary syndrome. *Vojnosanit Pregl* 2019; 76: 703–709.
36. Badawy A, State O, El Gawad SSA, et al. Plasma homocysteine and polycystic ovary syndrome: the missed link. *Eur J Obstet Gynecol Reprod Biol* 2007; 131: 68–72.
37. Bahat P, Özel A and Demirci A. Evaluation of carotid artery intima-media thickness as a cardiovascular risk factor in patients with polycystic ovary syndrome. *Cureus* 2021; 13: e13025.
38. Battaglia C, Mancini F, Cianciosi A, et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. *Obstet Gynecol* 2008; 111: 385–395.
39. Bayrak T, Dursun P, Bayrak A, et al. Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS. *Gynecol Endocrinol* 2012; 28: 874–878.
40. Bayraktar F, Dereli D, Ozgen AG, et al. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. *Endocr J* 2004; 51: 601–608.
41. Bhushan R and Sinha P. Correlation of serum homocysteine levels and hyperinsulinaemia with body mass index in polycystic ovarian syndrome. *J Hum Reprod Sci* 2022; 15: 34–41.
42. Caglar GS, Oztas E, Karadag D, et al. Ischemia-modified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance. *Fertil Steril* 2011; 95: 310–313.
43. Calzada M, López N, Noguera JA, et al. Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors. *J Endocrinol Invest* 2019; 42: 75–83.
44. Cao J and Wang H. Effect of blood homocysteine on the outcome of artificial insemination in women with polycystic ovary syndrome. *Biomed Res Int* 2022; 2022: 6311419.
45. Celik C, Bastu E, Abali R, et al. The relationship between copper, homocysteine and early vascular disease in lean women with polycystic ovary syndrome. *Gynecol Endocrinol* 2013; 29: 488–491.
46. Cetinkalp S, Karadeniz M, Erdogan M, et al. Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in western Anatolia, Turkey. *J Assist Reprod Genet* 2009; 26: 1–6.
47. Chang H, Xie L, Ge H, et al. Effects of hyperhomocysteinemia and metabolic syndrome on reproduction in women with polycystic ovary syndrome: a secondary analysis. *Reprod Biomed Online* 2019; 38: 990–998.
48. Cerqueira JMC, Costa LOBF, Nogueira Ade A, et al. Homocysteinemia in polycystic ovary syndrome women. *Rev Bras Ginecol Obstet* 2010; 32: 126–132.
49. Czerwonogrodzka-Senczyna A, Jerzak M, Jeznach-Steinhagen A, et al. Content of fatty acids in a diet and the homocysteine levels in women with fertility disorders. *Neuro Endocrinol Lett* 2018; 39: 56–64.
50. de la Calle M, Gallardo T, Diestro MD, et al. Increased homocysteine levels in polycystic ovary syndrome. *Med Clin (Barc)* 2007; 129: 292–294.

51. Deveer R, Engin-Üstün Y, Uysal S, et al. Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome. *Gynecol Endocrinol* 2012; 28: 602–605.
52. Lalitha Devi S and Abdul Jaweed S. Homocysteine, C-reactive protein and traditional cardiovascular risk markers in polycystic ovary syndrome. *Int J Cur Res Rev* 2013; 5: 59–68.
53. Dhanalakshmi G, Sumathi P, Pasupathi P, et al. Lipid profile and homocysteine level changes in metformin and metforminletrozole therapy with south Indian PCOS women. *Int J Cur Biomed Phar Res* 2011; 1: 102–108.
54. Diwaker A and Kishore D. Evaluation of plasma homocysteine levels in patients of PCOS. *J Assoc Physicians India* 2018; 66: 17–20.
55. El Gharib M, El Sabae T and Mabrouk M. Second trimester recurrent pregnancy loss in women with history of PCOS. *J Gynecol Res Obstet* 2016; 2: 1–4.
56. Eskandari Z, Sadrkhanlou RA, Nejati V, et al. PCOS women show significantly higher homocysteine level, independent to glucose and E2 level. *Int J Reprod Biomed* 2016; 14: 495–500.
57. Esmailzadeh S, Tahmasbpour E and Gholinezhad-Chari M. Hyperhomocysteinemia, insulin resistance and body mass index in Iranian young women with polycystic ovary syndrome. *Middle East Fertil Soc J* 2017; 22: 149–155.
58. Feng W, Zhang Y, Pan Y, et al. Association of three missense mutations in the homocysteine-related MTHFR and MTRR gene with risk of polycystic ovary syndrome in Southern Chinese women. *Reprod Biol Endocrinol* 2021; 19: 5.
59. Gözüküçük M, Gürsoy AY, Destegül E, et al. Homocysteine and C-reactive protein levels in women with polycystic ovary syndrome. *Gynecol Minim Invasive Ther* 2021; 10: 210–214.
60. Dokuz Eylül Güngör N, Çelik S, Güçlü M, et al. Evaluation of metabolic and hormonal parameters in women with PCOS living in Black Sea Region. *J Exp Clin Med (Turk)* 2021; 38: 235–240.
61. Chari S, Ghike S, Gupta MM, et al. Insulin resistance and homocysteine levels in patients with polycystic ovarian syndrome. *J S Asian Fed Obstet Gynecol* 2013; 5: 49–51.
62. Guzelmeric K, Alkan N, Pirimoglu M, et al. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. *Gynecol Endocrinol* 2007; 23: 505–510.
63. Hamadneh J, Al-bayyari NS, Hamadneh S, et al. Demographic, anthropometric, and biochemical characteristics of Jordanian women with polycystic ovary syndrome: a case-control study. *Int J Womens Health Reprod Sci* 2020; 9: 24–28.
64. Harmanci A, Cinar N, Bayraktar M, et al. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 2013; 78: 120–125.
65. Hemati T, Moghadami-Tabrizi N, Davari-Tanha F, et al. High plasma homocysteine and insulin resistance in patients with polycystic ovarian syndrome. *Iran J Reprod Med* 2011; 9: 223–228.
66. Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. *J Clin Endocrinol Metab* 2008; 93: 82–90.
67. İşbilen E and Karuserci Kömürçü Ö. Evaluation of the anti-inflammatory impact of vitamin D on polycystic ovary syndrome and endometriosis. *Experimed* 2022; 12: 80–84.
68. Karadeniz M, Erdogan M, Zengi A, et al. Methylene-tetrahydrofolate reductase C677T gene polymorphism in Turkish patients with polycystic ovary syndrome. *Endocrine* 2010; 38: 127–133.
69. Karaer A, Cavkaytar S, Mert I, et al. Cardiovascular risk factors in polycystic ovary syndrome. *J Obstet Gynaecol* 2010; 30: 387–392.
70. Kaya C, Cengiz SD and Satiroğlu H. Obesity and insulin resistance associated with lower plasma vitamin B12 in PCOS. *Reprod Biomed Online* 2009; 19: 721–726.
71. Kilic-Okman T, Guldiken S and Kucuk M. Relationship between homocysteine and insulin resistance in women with polycystic ovary syndrome. *Endocr J* 2004; 51: 505–508.
72. Krishna Mohan S and Priya VV. Lipid peroxidation, glutathione, ascorbic acid, vitamin E, antioxidant enzyme and serum homocysteine status in patients with polycystic ovary syndrome. *Biol Med* 2009; 1: 44–49.
73. Kulhan M, Kulhan NG, Nayki UA, et al. Assessment of the relationship between serum vitamin (A, B12, C, D, folate) and zinc levels and polycystic ovary syndrome. *Arch Med Sci Civil Dis* 2017; 2: 62–69.
74. Li T, Wu RJ, Liang QQ, et al. Analysis of serum homocysteine concentration in patients less than 35 years of age with polycystic ovary syndrome and hyperandrogenism. *Ginekol Pol* 2022; 2022: 20220823.
75. Loverro G, Lorusso F, Mei L, et al. The plasma homocysteine levels are increased in polycystic ovary syndrome. *Gynecol Obstet Invest* 2002; 53: 157–162.
76. Maleedhu P, Vijayabhaskar M, Sharma SB, et al. Status of homocysteine in polycystic ovary syndrome (PCOS). *J Clin Diagn Res* 2014; 8: 31–33.
77. Miranda-Furtado CL, Ramos FKP, Kogure GS, et al. A non-randomized trial of progressive resistance training intervention in women with polycystic ovary syndrome and its implications in telomere content. *Reprod Sci* 2016; 23: 644–654.
78. Moran LJ, Noakes M, Clifton PM, et al. Genome instability is increased in lymphocytes of women with polycystic ovary syndrome and is correlated with insulin resistance. *Mutat Res* 2008; 639: 55–63.
79. Moti M, Amini L, Mirhoseini Ardakani SS, et al. Oxidative stress and anti-oxidant defense system in Iranian women with polycystic ovary syndrome. *Iran J Reprod Med* 2015; 13: 373–378.
80. Nafiye Y, Sevtap K, Muammer D, et al. The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome. *Fertil Steril* 2010; 93: 1864–1869.
81. Mohamed AN, Mohammed NB, Eltom A, et al. The relationship between BMI and age with lipid peroxidation, antioxidant enzyme super oxide dismutase glutathione and serum homocysteine level in polycystic ovary syndrome in sudanese patients. *Sch Int J Obstet Gynecol* 2020; 3: 232–240.

82. Al-Faris NN, Al-Tu'ma FJ and Al-Safi WG. Total antioxidant capacity and homocysteine levels in obese women with polycystic ovary syndrome. *Int J Pharm Pharm Res* 2017; 8: 78–86.
83. Oktem M, Ozcimen EE, Uckuyu A, et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. *Fertil Steril* 2009; 91: 2545–2550.
84. Onwumere K, Musa BP, Kolawole A, et al. Serum homocystein and C-reactive protein in predicting outcome of in-vitro fertilization in infertile women with polycystic ovary syndrome. *Afr J Infertil Assist Concept* 2021; 6: 14–19.
85. Orio F Jr, Palomba S, Di Biase S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003; 88: 673–679.
86. Palep-Singh M, Picton HM, Yates ZR, et al. Plasma homocysteine concentrations and the single nucleotide polymorphisms in the methionine synthase gene (MTR 2756A>G): associations with the polycystic ovary syndrome an observational study. *Eur J Obstet Gynecol Reprod Biol* 2008; 138: 180–186.
87. Peña-Paredes E, Reyna Villasmil E, Torres Cepeda D, et al. Homocisteína plasmática en pacientes con hiperprolactinemia o con síndrome de ovarios poliquísticos. *MedULA Rev Fac Med* 2008; 17: 102–107.
88. Rekha S, Patel ML, Pooja G, et al. Correlation between elevated homocysteine levels and insulin resistance in infertile women with or without polycystic ovary syndrome in north Indian population. *Int J Med Sci* 2013; 5: 116–123.
89. Roshni G, Sadaria and Smita N. Vasava. Association of BMI with Serum Homocysteine in Polycystic Ovarian Syndrome Women. *Indian J Forensic Med Toxicol* 2021; 15: 686–690.
90. Sahin Y, Unluhizarci K, Yilmazsoy A, et al. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 2007; 67: 904–908.
91. Salehpour S, Manzor-Al-Ajdad O, Samani EN, et al. Evaluation of homocysteine levels in patients with polycystic ovarian syndrome. *Int J Fertil Steril* 2011; 4: 168–171.
92. Schachter M, Razieli A, Strassburger D, et al. Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. *Fertil Steril* 2007; 88: 227–230.
93. Soares GM, Vieira CS, Martins WP, et al. Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome? *Clin Endocrinol (Oxf)* 2009; 71: 406–411.
94. Sohrabvand F, Lankarani M, Golestan B, et al. Serum homocysteine levels in PCOS patients versus healthy women. *J Reprod Infertil* 2009; 9: 334–342.
95. Suleiman R and Sulaiman D. Studying levels of homocysteine in diagnosed cases of polycystic ovary syndrome. *Med J Babylon* 2018; 15: 291–294.
96. Tarkun ÇB, Çetinarıslan B, Cantürk Z, et al. The plasma homocysteine concentrations and relationship with insulin resistance in young women with polycystic ovary syndrome. *Turk J Endocrinol Metab* 2005; 9: 23–28.
97. Temel İ, Çelik Ö, Haşçalık Ş, et al. Serum nonesterified fatty acids, ghrelin, and homocysteine levels in women with polycystic ovary syndrome. *Turk J Med Sci* 2010; 40: 90.
98. Topcu S, Caliskan M, Ozcimen EE, et al. Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease? *Hum Reprod* 2006; 21: 930–935.
99. Vrbíková J, Tallová J, Biciková M, et al. Plasma thiols and androgen levels in polycystic ovary syndrome. *Clin Chem Lab Med* 2003; 41: 216–221.
100. Wijeyaratne CN, Nirantharakumar K, Balen AH, et al. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? *Clin Endocrinol (Oxf)* 2004; 60: 560–567.
101. Yarali H, Yildirim A, Aybar F, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. *Fertil Steril* 2001; 76: 511–516.
102. Yilmaz M, Biri A, Bukan N, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. *Gynecol Endocrinol* 2005; 20: 258–263.
103. Yilmaz M, Bukan N, Ayvaz G, et al. The effects of Rosiglitazone and Metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. *Hum Reprod* 2005; 20: 3333–3340.
104. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004; 19: 41–47.
105. Zawadski JK and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al. (eds.) *Polycystic ovary syndrome (current issues in endocrinology and metabolism)*. Boston: Blackwell Publishing Scientific Inc., 1992, p. 377.
106. Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. *Hum Reprod* 2002; 17: 2495–2499.
107. Kumar A, Palfrey HA, Pathak R, et al. The metabolism and significance of homocysteine in nutrition and health. *Nutr Metab (Lond)* 2017; 14: 20171222.
108. Azzini E, Ruggeri S and Polito A. Homocysteine: its possible emerging role in at-risk population groups. *Int J Mol Sci* 2020; 21: 20200220.
109. Schiuma N, Costantino A, Bartolotti T, et al. Micronutrients in support to the one carbon cycle for the modulation of blood fasting homocysteine in PCOS women. *J Endocrinol Invest* 2020; 43: 779–786.
110. Kucuk T, Horozal PE, Karakulak A, et al. Follicular homocysteine as a marker of oocyte quality in PCOS and the role of micronutrients. *J Assist Reprod Genet* 2023; 40: 1933–1941.
111. Matorras R, Pijoan JI, Lainz L, et al. Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis. *Arch Gynecol Obstet* 2023; 308: 363–377.
112. Peeva M, Badeghiesh A, Baghlaif H, et al. Adverse obstetric outcomes in women with PCOS and multiple gestations. *Reprod Biomed Online* 2023; 46: 379–389.
113. Chakraborty P, Mitra I, Kalapahar S, et al. Significance of hyperhomocysteinemia in immediate as well as long-term

- health risk/s in women with polycystic ovary syndrome: a probabilistic model using dynamic bayesian network analysis. *Reprod Sci* 2023; 30: 1207–1216.
114. Son P and Ćewis L. *Hyperhomocysteinemia*. Treasure Island, FL: StatPearls, 2022.
115. Meng Y, Chen X, Peng Z, et al. Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and meta-analysis. *PLoS One* 2016; 11: e0157389.
116. Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. *Hum Reprod Update* 2011; 17: 741–760.
117. Benites-Zapata VA, Ignacio-Cconchoy FL, Ulloque-Badaracco JR, et al. Vitamin B12 levels in thyroid disorders: a systematic review and meta-analysis. *Front Endocrinol* 2023; 14: 1070592.
118. Xiong Y, Bian C, Lin X, et al. Methylenetetrahydrofolate reductase gene polymorphisms in the risk of polycystic ovary syndrome and ovarian cancer. *Biosci Rep* 2020; 40: BSR20200995.
119. Grodnitskaya EE and Kurtser MA. Homocysteine metabolism in polycystic ovary syndrome. *Gynecol Endocrinol* 2012; 28: 186–189.
120. Bagos PG. Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. *Mol Hum Reprod* 2009; 15: 19–26.
121. Sahin M, Tutuncu NB, Ertugrul D, et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. *J Diabetes Complications* 2007; 21: 118–123.
122. Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. *Hum Reprod* 2005; 20: 894–899.
123. Luque-Ramírez M, Mendieta-Azcona C, del Rey Sánchez JM, et al. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. *Eur J Endocrinol* 2009; 160: 469–480.
124. Urbíková J, Bicíková M, Tallová J, et al. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. *Exp Clin Endocrinol Diabetes* 2002; 110: 74–76.
125. Wang J, You D, Wang H, et al. Association between homocysteine and obesity: a meta-analysis. *J Evid Based Med* 2021; 14: 208–217.
126. Li X, Fang Z, Yang X, et al. The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. *J Obstet Gynaecol Res* 2021; 47: 1804–1816.
127. Kamrul-Hasan A and Aalpona FTZ. Comparison of serum vitamin B12 levels among drug-naïve and metformin-treated patients with polycystic ovary syndrome. *Cureus* 2022; 14: e30447.
128. Jafari A, Gholizadeh E, Sadrmanesh O, et al. The effect of folic acid supplementation on body weight and body mass index: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr ESPEN* 2023; 53: 206–213.